Evidence map›Paper›PMID 30402660›Full record

ReviewCardiovascular drugs and therapy2018

Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.

S Bouchez, F Fedele, G Giannakoulas, F Gustafsson, V-P Harjola, K Karason, M Kivikko, D von Lewinski, F Oliva, Z Papp and 4 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 14 institutions in 9 countries.

S BouchezDepartment of Anesthesiology, University Hospital, Ghent, Belgium.
F FedelePoliclinico "Umberto I," University "La Sapienza", Rome, Italy.
G GiannakoulasAristotle University of Thessaloniki, Thessaloniki, Greece.
F GustafssonCardiology, Rigshospitalet, Copenhagen, Denmark.
V-P HarjolaCardiology Clinic, HUS Meilahti Hospital, Helsinki, Finland.
K KarasonCardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
M KivikkoCritical Care Proprietary Products Division, Orion Pharma, P.O. Box 65, FIN-02101, Espoo, Finland.
D von LewinskiMyokardiale Energetik und Metabolismus Research Unit, Medical University, Graz, Austria.
F OlivaNiguarda Ca'Granda Hospital, Milan, Italy.
Z PappDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
J ParissisSecond University Cardiology Clinic, Attiko Teaching Hospital, Athens, Greece.
Piero PolleselloCritical Care Proprietary Products Division, Orion Pharma, P.O. Box 65, FIN-02101, Espoo, Finland. piero.pollesello@gmail.com.ORCID 0000-0001-6994-768X
G PölzlUniversitätsklinik für Innere Medizin III Innsbruck, Medizinsche Universität, Innsbruck, Austria.
C TschöpeBerlin Center for Regenerative Therapies (BCRT), Campus Virchow Klinikum (CVK), Berlin, Germany.
Aristotle University of Thessaloniki · GRAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITBerlin-Brandenburger Centrum für Regenerative Therapien · DEGhent University Hospital · BEHerttoniemi Hospital · FIInnsbruck Medical University · ATJorvi Hospital · FIMedical University of Graz · ATOrion Corporation (Finland) · FIPoliclinico Umberto I · ITRigshospitalet · DKSahlgrenska University Hospital · SEUniversity General Hospital Attikon · GRUniversity of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many specialist heart failure practitioners for its effects on systemic and pulmonary hemodynamics and for the relief of symptoms of acute heart failure. The drug's impact on mortality in large randomized controlled trials has been inconsistent or inconclusive but, in contrast to conventional inotropes, there have been no indications of worsened survival and some signals of improved heart failure-related quality of life. For this reason, levosimendan has been proposed as a safer inodilator option than traditional agents in settings, such as advanced heart failure. Positive effects of levosimendan on renal function have also been described. At the HEART FAILURE 2018 congress of the Heart Failure Association of the European Society of Cardiology, safe and effective use levosimendan in acute and advanced heart failure was examined in a series of expert tutorials. The proceedings of those tutorials are summarized in this review, with special reference to advanced heart failure and heart failure with concomitant renal dysfunction. Meta-analysis of clinical trials data is supportive of a renal-protective effect of levosimendan, while physiological observations suggest that this effect is exerted at least in part via organ-specific effects that may include selective vasodilation of glomerular afferent arterioles and increased renal blood flow, with no compromise of renal oxygenation. These lines of evidence require further investigation and their clinical significance needs to be evaluated in specifically designed prospective trials.

Indexed as

Acute DiseaseCardiotonic AgentsChronic DiseaseCongresses as TopicEvidence-Based MedicineHeart FailureHumansKidneyMyocardial ContractionRecovery of FunctionSimendanTime FactorsTreatment OutcomeVasodilator AgentsCardiotonic AgentsSimendanVasodilator AgentsAcute heart failureAdvanced heart failureInodilatorsInotropesLevosimendanRenal function

Identifiers

PMID30402660
PMCPMC6267661
OpenAlexW2900163582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.